IMMUNEONCO-B Tumbles 6.6% as Revenue Growth Fails to Impress

Edgen Stock

·Mar 25 2026, 18:27

Share to

Share to

Copy link

Key Takeaways

IMMUNEONCO-B (01541.HK) released its 2025 annual results, showcasing significant revenue growth and reduced losses. However, the market reacted negatively, with the stock falling sharply as the positive developments appeared insufficient to meet investor expectations or alleviate concerns about future profitability.

Revenue Jumps 108.1%: The company reported total revenue of RMB154 million for the 2025 fiscal year, more than doubling its top line from the previous year.
Losses Narrow to RMB219 Million: The firm's net loss decreased from RMB316 million in the prior year, bringing the loss per share to RMB0.53.
Market Sells Off on News: Despite the improved financial metrics, the company's stock fell 6.638% immediately following the announcement, indicating a bearish investor sentiment.

Revenue Doubles to RMB154 Million as Losses Shrink

On March 25, 2026, IMMUNEONCO-B (01541.HK) reported its 2025 annual results, highlighting a 108.1% year-over-year increase in revenue to RMB154 million. The Hong Kong-listed biotechnology company also demonstrated progress in its financial management by narrowing its net loss to RMB219 million, a notable improvement from the RMB316 million loss recorded in the previous year. This translated to a loss per share of RMB0.53. In its announcement, the company confirmed that no final dividend would be distributed to shareholders.

Stock Slides 6.6% in Post-Earnings Sell-Off

The market reacted unfavorably to the financial update, causing shares of IMMUNEONCO-B to fall by 6.638%. The decline was accompanied by short-selling activity amounting to $100,520, signaling negative sentiment. This price action suggests that the positive top-line growth and reduced losses were either already priced into the stock or were not strong enough to meet investor expectations. The sell-off points to underlying concerns about the company's path to profitability and its decision to forgo a dividend, creating a classic "sell the news" event that could apply further pressure on the stock.